OMA Guidelines Bundle

Obesity Pharmacotherapy - Obesity Algorithm 2024

Obesity Medicine Association OMA GUIDELINES App Bundle brought to you courtesy of Guideline Central. All of these titles are available for purchase on our website, GuidelineCentral.com. Enjoy!

Issue link: https://eguideline.guidelinecentral.com/i/1349812

Contents of this Issue

Navigation

Page 17 of 33

18 Anti-obesity Pharmacotherapy Eating Disorders and Miscellaneous Agent/Dose Description Main Side Effects/ Adverse Reactions Setmelanotide (IMCIVREE™) Dose: Age ≥6 years: 1–3mg subcut QD Melanocortin-4 receptor agonist Injection site reactions, skin hyperpigmentation, nausea, headache, diarrhea, abdominal pain, back pain, fatigue, vomiting, depression, upper respiratory tract infection, and spontaneous penile erection. Metreleptin Subcutaneous Injection (Myalept ® ) Starting Dose: 2.5 mg (men), 5 mg (women) subcut QD Max: 10 mg QD Leptin analog indicated for congenital or acquired generalized lipodystrophy Headache, hypoglycemia, decreased weight, abdominal pain Fluoxetine Indication: Bulimia nervosa Dose: 60 mg QD Serotonin re-uptake inhibitors Abnormal dreams, abnormal ejaculation, anorexia, anxiety, asthenia, diarrhea, dry mouth, dyspepsia, flu syndrome, impotence, insomnia, decreased libido, nausea, nervousness, pharyngitis, rash, sinusitis, somnolence, sweating, tremor, vasodilatation, and yawning

Articles in this issue

Archives of this issue

view archives of OMA Guidelines Bundle - Obesity Pharmacotherapy - Obesity Algorithm 2024